Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM
The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.
Bispecifics in Development for the Treatment of R/R MM
Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.
Treatment Options for Patients with Relapsed Multiple Myeloma
Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.
Defining Frail Patients in Multiple Myeloma
Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.
Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM
Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.
Data Updates in Transplant Ineligible NDMM
Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.
Selecting Frontline Treatment Regimens for Transplant-Ineligible MM
Dr Varga and Dr Tuchman explain the factors for consideration when choosing an initial treatment regimen for patients with transplant-ineligible NDMM.
Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma
Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.
Assessing Response and Duration of Treatment in Transplant-Eligible NDMM
Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.
Evaluating MRD-Guided Therapy in Patients with NDMM
Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.
Patient Profile: A 59-Year-Old Man with Transplant Eligible Newly-Diagnosed Multiple Myeloma (NDMM)
Cindy Varga, MD, presents a profile of a 59-year-old patient diagnosed with transplant-eligible multiple myeloma.
Available Induction Regimen Options for Patients with Transplant-Eligible NDMM
The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.
Optimizing Therapy in Frontline Multiple Myeloma Not Eligible for Transplant
Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.
Future Directions in Multiple Myeloma Care: Improvements and Unmet Needs
After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.
Patient Case #2: A 77-Year-Old Man With Newly Diagnosed MM
Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.
Patient Case #1: A 75-Year-Old Woman With Newly Diagnosed MM
Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.
Treatment Options for First-Line Therapy in Transplant-Ineligible MM
In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.
Transplant-Ineligible MM: Treatment After Adequate Response to Therapy
A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.
Transplant-Ineligible Multiple Myeloma: Assessing Response to Therapy
Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.
Multiple Myeloma: Transplant Ineligibility and Goals of Therapy
Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.
Challenges in Treating Transplant-Ineligible Multiple Myeloma
Shared insight on the difficulties of transplant-ineligible newly diagnosed multiple myeloma and how to optimally approach treatment.
Peter Voorhees, MD, on Sustained MRD Negativity in the Phase 2 GRIFFIN Trial
The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).
Peter Voorhees, MD, Discusses Updated Analysis of Phase 2 GRIFFIN Trial in MM
The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.
Peter Voorhees, MD on the Progress Made in 2020 For Patients With Multiple Myeloma
Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.
Peter Voorhees, MD, Discusses Results from the Ongoing GRIFFIN Study
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512